Sugi Predict

Sugi Predict / Compounds / SCHEMBL3485904

SCHEMBL3485904

SCHEMBL3485904

COC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@](C)(F)[C@@H]1O)Oc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.57
▸ CYP2C9 P11712 2/20 0.57
▸ NT5E P21589 1/20 0.43
▸ ADORA2A P29274 1/20 0.42
▸ P2RY12 Q9H244 3/20 0.42
▸ P2RY1 P47900 4/20 0.42
▸ P2RY2 P41231 3/20 0.42
▸ DNPH1 O43598 1/20 0.42
▸ PRKAB2 O43741 1/20 0.42
▸ TRPM2 O94759 1/20 0.42
▸ LDHA P00338 1/20 0.42
▸ ADRB2 P07550 1/20 0.42
▸ FBP1 P09467 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ PRKAG1 P54619 1/20 0.42
▸ PRKAA2 P54646 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ PRKAA1 Q13131 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16174662 1.00 CYP3A4 (0.57) CYP3A4CYP2C9NT5EADORA2AP2RY12
SCHEMBL14367294 0.92 ADORA2A (0.52) CYP3A4CYP2C9NT5EADORA2AP2RY12
SCHEMBL23597931 0.92 CYP3A4 (0.49) CYP3A4CYP2C9NT5EADORA2AP2RY12
SCHEMBL3484865 0.91 CYP3A4 (0.57) CYP3A4CYP2C9NT5EADORA2AP2RY12
SCHEMBL22837350 0.91 CYP3A4 (0.57) CYP3A4CYP2C9ADORA2AP2RY12DNPH1
SCHEMBL3485778 0.91 CYP3A4 (0.57) CYP3A4CYP2C9NT5E
SCHEMBL22837361 0.91 CYP3A4 (0.57) CYP3A4CYP2C9ADORA2AP2RY12DNPH1
SCHEMBL22837362 0.91 CYP3A4 (0.57) CYP3A4CYP2C9ADORA2AP2RY12DNPH1
SCHEMBL23790861 0.91 CYP3A4 (0.57) CYP3A4CYP2C9ADORA2AP2RY12DNPH1
SCHEMBL22837351 0.91 CYP3A4 (0.57) CYP3A4CYP2C9ADORA2AP2RY12DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288020-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC (US) 2014-09-25 — — US claimed
EP-2203462-A2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS Pharmasset, Inc. (US) 2010-07-07 — — EP claimed
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2010-01-21 — — US claimed
WO-2008121634-A2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2008-10-09 — — WO claimed
EP-4282482-A2 Nucleoside phosphoramidate prodrugs Gilead Sciences, Inc. (US) 2023-11-29 — — EP disclosed
US-11642361-B2 Nucleoside phosphoramidate prodrugs GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-11642361-B2 Nucleoside phosphoramidate prodrugs GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
US-20210196741-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC 2021-07-01 — — US disclosed
US-10183037-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2019-01-22 — — US disclosed
US-20180000855-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD SCIENCES, INC. 2018-01-04 — — US disclosed
US-9585906-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2017-03-07 — — US disclosed
US-9585906-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2017-03-07 — — US disclosed
US-8334270-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2012-12-18 — — US disclosed
US-20110257122-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2011-10-20 — — US disclosed
US-20110257122-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2011-10-20 — — US disclosed
US-7964580-B2 Nucleoside phosphoramidate prodrugs PHARMASSET, INC. (US) 2011-06-21 — — US disclosed
US-7964580-B2 Nucleoside phosphoramidate prodrugs PHARMASSET, INC. (US) 2011-06-21 — — US disclosed
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2010-01-21 — — US disclosed
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2010-01-21 — — US disclosed
WO-2008121634-A2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885
US-11642361-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885
US-20180000855-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885
US-20110257122-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885
US-20140288020-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885
US-20210196741-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885
US-10183037-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP CYP3A4 1268/4885CYP2C9 868/4885NT5E 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.